This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
Cracking the CRS Code in Myeloma: Insights from a Comprehensive Case Review
The Latest Insights into Rare Blood Disorders: Diagnosis and Treatment Strategies
Unlocking the Potential of TROP2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
A Roadmap to Safe and Effective Bispecific Antibody Use in Myeloma: Mitigating and Managing Adverse Events
Ultrasound Renal Denervation: Interdisciplinary Approach to Better Patient Outcomes
Later-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers
Safety and Tolerability of ROS1 Tyrosine Kinase Inhibitors
The Role of Chemotherapy and Immunotherapy in ROS1-Rearranged NSCLC
Treatment Strategy of ROS1-Rearranged NSCLC in TKI-Naive Patient
Case: Treatment Selection for ROS1-Rearranged NSCLC Patient with Brain Metastases
Overcoming Acquired TKI-Resistance with Next-generation ROS1-TKI Agents
Intracranial Activity of ROS1 TKIs
Current Guidelines and Real-World Evidence for ROS1 Testing in NSCLC
First-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers
Clinical Challenges With Triple-Class or Penta-Refractory MM
Bispecific Antibodies: The Newest Immunotherapy on the Block for RRMM
Integrating Bispecific Antibodies Into Clinical Practice
The Evolving Treatment Paradigm for RRMM: The Role of Bispecific Antibodies
Create your
podcast in
minutes
It is Free
RenaissanceOnlineRadio.com
Men in Lead Aprons
Denver Underground
Exercise: Learn To Love (Or At Least Like) It
NASACast Video